Timberlyne Therapeutics
PrivateLast Round
Series A
Jan 9, 2025
Est. Valuation
$242.6M
Total Funding Raised
$180M
Company Overview
Timberlyne Therapeutics operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series A round in January 2025.
Timberlyne Therapeutics is a biotechnology company that develops and commercializes monoclonal antibody therapies for autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Timberlyne Therapeutics Comparables
Compare Timberlyne Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Biogen | 81% | |
| Hangzhou Shangjian Biotechnology Co., Ltd. | 79% | |
| CASI Pharmaceuticals | 78% |
For institutional investors. Book with your work email.
Timberlyne Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Timberlyne Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Life Sciences | Series A |
| Boyu Capital | Series A |
| Mountainfield Venture Partners | Series A |
| Braidwell | Series A |
| 3H Health Investment | Series A |
| Abingworth | Series A |
| Lilly Asia Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 9, 2025
$180M round raised
For institutional investors. Book with your work email.
Timberlyne Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Timberlyne Therapeutics's valuation, stock price, and market status.
Is Timberlyne Therapeutics a public or private company?
Timberlyne Therapeutics is a private company.
What is the current stock price of Timberlyne Therapeutics?
Timberlyne Therapeutics is a private company, so its shares have no public market price. Caplight tracks Timberlyne Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Timberlyne Therapeutics worth (valuation)?
Timberlyne Therapeutics's valuation is estimated at $242.6M based on funding round data.
Can I buy Timberlyne Therapeutics stock?
Timberlyne Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Timberlyne Therapeutics's last funding round?
Timberlyne Therapeutics's most recent funding round was Series A on January 9, 2025.
Who are the main investors in Timberlyne Therapeutics?
Key investors in Timberlyne Therapeutics include Bain Capital Life Sciences, Abingworth, Venrock.
Will Timberlyne Therapeutics IPO soon?
No public IPO plans have been announced for Timberlyne Therapeutics.
How can I track Timberlyne Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Timberlyne Therapeutics's shares on secondary markets.